CA2874700A1 - Formulations injectables d'aprepitant - Google Patents

Formulations injectables d'aprepitant Download PDF

Info

Publication number
CA2874700A1
CA2874700A1 CA2874700A CA2874700A CA2874700A1 CA 2874700 A1 CA2874700 A1 CA 2874700A1 CA 2874700 A CA2874700 A CA 2874700A CA 2874700 A CA2874700 A CA 2874700A CA 2874700 A1 CA2874700 A1 CA 2874700A1
Authority
CA
Canada
Prior art keywords
aprepitant
solvent
surfactant
primary
liquid formulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2874700A
Other languages
English (en)
Inventor
Tushar HINGORANI
Kumaresh Soppimath
Satish Pejaver
Navneet Puri
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Innopharma Inc
Original Assignee
Innopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Innopharma Inc filed Critical Innopharma Inc
Publication of CA2874700A1 publication Critical patent/CA2874700A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA2874700A 2012-05-24 2013-05-24 Formulations injectables d'aprepitant Abandoned CA2874700A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261651501P 2012-05-24 2012-05-24
US61/651,501 2012-05-24
US201361798276P 2013-03-15 2013-03-15
US61/798,276 2013-03-15
PCT/US2013/042618 WO2013177501A2 (fr) 2012-05-24 2013-05-24 Formulations injectables d'aprépitant

Publications (1)

Publication Number Publication Date
CA2874700A1 true CA2874700A1 (fr) 2013-11-28

Family

ID=49622077

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2874700A Abandoned CA2874700A1 (fr) 2012-05-24 2013-05-24 Formulations injectables d'aprepitant

Country Status (15)

Country Link
US (2) US20130317016A1 (fr)
EP (1) EP2855436A4 (fr)
JP (1) JP2015521190A (fr)
KR (1) KR20150022839A (fr)
CN (1) CN104619312A (fr)
AU (1) AU2013266141B2 (fr)
BR (1) BR112014029176A2 (fr)
CA (1) CA2874700A1 (fr)
HK (1) HK1203193A1 (fr)
IL (1) IL235864A0 (fr)
MX (1) MX2014014173A (fr)
NZ (1) NZ702114A (fr)
RU (1) RU2014147365A (fr)
SG (1) SG11201407765VA (fr)
WO (1) WO2013177501A2 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3054980B1 (fr) * 2013-10-08 2019-09-04 InnoPharma, Inc. Formulations liquides orales d'aprépitant
CA2956022A1 (fr) * 2014-07-24 2016-01-28 Plus Vitech,S.L Composition d'antagoniste de recepteur de neurokinine-1 pour le traitement de maladies et d'affections des voies respiratoires
WO2016044784A1 (fr) 2014-09-19 2016-03-24 Heron Therapeutics, Inc. Formulations d'émulson d'aprépitant
TWI586379B (zh) * 2015-06-29 2017-06-11 永信藥品工業股份有限公司 一種製作難溶藥物固體劑型的方法
US9913853B2 (en) 2015-11-03 2018-03-13 Cipla Limited Stabilized liquid fosaprepitant formulations
US9974742B2 (en) 2016-02-01 2018-05-22 Heron Therapeutics, Inc. Emulsion formulations of an NK-1 receptor antagonist and uses thereof
JP6829257B2 (ja) * 2016-02-01 2021-02-10 ヘロン セラピューティクス， インコーポレイテッドＨｅｒｏｎ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． Ｎｋ−１受容体アンタゴニストを含むエマルジョン
EP4019023A1 (fr) * 2016-08-03 2022-06-29 Zhuhai Beihai Biotech Co., Ltd. Formulations de fosaprépitant et d'aprépitant
US11065265B2 (en) 2018-05-18 2021-07-20 Spes Pharmaceuticals Inc. Compositions of fosaprepitant and methods of preparation
CN112168788B (zh) * 2019-07-01 2022-07-19 中国医学科学院药物研究所 静脉注射用阿瑞匹坦胶束无菌冻干制剂及其制备方法
CN112190546A (zh) * 2019-07-08 2021-01-08 苏州海特比奥生物技术有限公司 一种阿瑞匹坦制剂的制备方法
JP6832468B1 (ja) * 2020-07-15 2021-02-24 キユーピー株式会社 エマルジョン、注射剤、及びエマルジョンを調製する方法
CN113712915A (zh) * 2021-01-07 2021-11-30 广州曼翔医药有限公司 一种阿瑞匹坦乳状注射液的制备方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2548078C (fr) * 2003-12-17 2009-05-12 Bionumerik Pharmaceuticals, Inc. Preparations pharmaceutiques de camptothecines et leur procede d'obtention
EP2767163A1 (fr) * 2005-02-17 2014-08-20 Abbott Laboratories Administration par voie transmuqueuse de compositions médicamenteuses pour le traitement et la prévention de troubles chez les animaux
US8133994B2 (en) * 2005-10-06 2012-03-13 Dr. Reddy's Laboratories Ltd. Preparation of aprepitant
KR20080089659A (ko) 2006-02-03 2008-10-07 그렌마크 파머수티칼스 엘티디. 아프레피탄트의 비정질 및 결정 형태 및 그것의 제조 방법
WO2007112457A2 (fr) 2006-03-29 2007-10-04 Dr. Reddy's Labortories, Ltd. Mélanges polymorphes de l'aprépitant
US20090209541A1 (en) * 2006-06-16 2009-08-20 Dr. Reddy's Laboratories Ltd. Aprepitant compositions
JP5523829B2 (ja) 2006-06-29 2014-06-18 アステックス、セラピューティックス、リミテッド 複合薬剤
US20110015191A1 (en) 2007-02-27 2011-01-20 Sandoz Ag Organic compounds
US20100151035A1 (en) 2007-03-13 2010-06-17 Sandoz Ag Pharmaceutical compositions of poorly soluble drugs
WO2009108828A2 (fr) 2008-02-27 2009-09-03 Dr. Reddy's Laboratories Ltd. Formes d'aprépitant avec une meilleure solubilité et leurs compositions pharmaceutiques
WO2010140132A1 (fr) 2009-06-02 2010-12-09 Ranbaxy Laboratories Limited Procédé pour la préparation d'aprépitant cristallin ayant une teneur en forme i
HUP1000325A2 (en) * 2010-06-18 2012-01-30 Druggability Technologies Ip Holdco Jersey Ltd Nanostructured aprepitant compositions and process for their preparation
WO2011161531A1 (fr) * 2010-06-24 2011-12-29 Torrent Pharmaceuticals Limited Composition pharmaceutique contenant de la goséréline pour un implant in situ
CN102379845A (zh) * 2011-11-03 2012-03-21 南京优科生物医药有限公司 一种注射用阿瑞匹坦微乳剂及其制备方法

Also Published As

Publication number Publication date
AU2013266141A1 (en) 2014-12-11
US9968614B2 (en) 2018-05-15
RU2014147365A (ru) 2016-07-20
KR20150022839A (ko) 2015-03-04
WO2013177501A2 (fr) 2013-11-28
EP2855436A4 (fr) 2016-01-06
BR112014029176A2 (pt) 2017-06-27
AU2013266141B2 (en) 2015-10-01
WO2013177501A3 (fr) 2014-01-30
HK1203193A1 (en) 2015-10-23
JP2015521190A (ja) 2015-07-27
US20170136027A1 (en) 2017-05-18
SG11201407765VA (en) 2015-01-29
US20130317016A1 (en) 2013-11-28
MX2014014173A (es) 2015-07-21
IL235864A0 (en) 2015-02-01
EP2855436A2 (fr) 2015-04-08
NZ702114A (en) 2016-02-26
WO2013177501A4 (fr) 2014-03-20
CN104619312A (zh) 2015-05-13

Similar Documents

Publication Publication Date Title
US9968614B2 (en) Aprepitant injectable formulations
US20110281901A1 (en) Pharmaceutical compositions and methods of making same
BR112012033077B1 (pt) composição farmacêutica para administração intravenosa, uso de uma composição farmacêutica, e, kit
WO2017127835A2 (fr) Formulations aqueuses, et procédés de préparation et d'utilisation de celles-ci
US11129833B2 (en) Methotrexate formulation
TW202114653A (zh) 口服紫杉烷組合物及方法
US20090275647A1 (en) Taxane derivative composition
US20170304451A1 (en) Parenteral compositions of bendamustine
US20100216751A1 (en) Liquid Bevirimat Dosage Forms for Oral Administration
US11857677B2 (en) Ready to use injectable formulations of melphalan and processes for preparation thereof
WO2014108918A2 (fr) Formulation antifongique injectable
US7022712B2 (en) Solubilization of weak bases
US20190070136A1 (en) Parenteral compositions of carmustine
US20090062295A1 (en) Pharmaceutical Products
US7687516B2 (en) Alcohol free formulation of argatroban
WO2009098649A1 (fr) Poudre pour suspension orale d'un macrolide immunosuppresseur
US20150174097A1 (en) Treating ewing's sarcoma and ews-fli1 related disorders
EP4055005A1 (fr) Composition liquide de melphalan
WO2024009319A1 (fr) Compositions injectables liquides de trilaciclib
IL290647B2 (en) Pemetrexed formulations
US20100152244A1 (en) Self-emulsifying formulation of tipranavir for oral administration
WO2016079749A2 (fr) Procédé de préparation de formulation parentérale d'anidulafungine
WO2007073112A1 (fr) Composition comportant un medicament antifongique a base d'azole et son procede de preparation

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20141124

FZDE Discontinued

Effective date: 20170524